Structure Therapeutics Inc ADR

GPCRNASDAQ · USD
36.81USD0.00 (+5.18%)
2110

Structure Therapeutics Inc ADR (GPCR) Straddle

GPCR straddle scan found 105 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 57.8%.

Read more

Trading a GPCR straddle lets you take a pure volatility position on Structure Therapeutics Inc ADR without committing to a direction. Structure Therapeutics Inc ADR's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate GPCR straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on GPCR profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Structure Therapeutics Inc ADR stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the GPCR straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF.

The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the GPCR straddle is the cleanest expression of that view. Our scanner prices every GPCR straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a GPCR straddle into a catalyst or short a GPCR straddle to harvest decay, the options straddle setups that matter are all in one place.

Jan 21, 2028140.00$106.934912%57.8%$246.93$33.080
Jan 21, 2028105.00$72.754912%56.7%$177.75$32.250
Jan 21, 202897.50$66.004912%55.6%$163.50$31.500
Oct 16, 202650.00$14.50292%55.3%$64.50$35.5037
Jan 21, 2028100.00$68.684912%55.2%$168.68$31.330
Jan 21, 202892.50$61.504912%54.9%$154.00$31.000
Jan 21, 202895.00$64.004912%54.8%$159.00$31.000
Jan 21, 202890.00$59.254912%54.6%$149.25$30.750
Jan 21, 202885.00$55.004912%53.4%$140.00$30.000
Jan 21, 202887.50$57.504912%53.3%$145.00$30.000

As of September 21, 2026

Find the right straddle before volatility moves

Track GPCR straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.

Start your 14-day free trial